PRECISION BIOSCIENCES INC Cash Flow Statement
DTIL|7 years of annual SEC 10-K data (FY2019-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 7 fiscal years. All figures from audited SEC 10-K filings.
PRECISION BIOSCIENCES INC used $58M in operating cash flow and negative free cash flow of $59M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.67 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Income | $7.2M | -$61.3M | -$111.6M | -$30.6M | -$109.0M | -$92.9M | -$46.0M |
| Depreciation & Amortization | $3.4M | $6.8M | $7.8M | $9.0M | $8.8M | $5.3M | $2.4M |
| Operating Cash Flow | -$58.4M | -$84.1M | -$45.8M | -$10.9M | -$87.4M | -$71.0M | -$51.7M |
| Capital Expenditures | $250.0K | $2.0M | $3.3M | $5.1M | $5.0M | $24.7M | $14.3M |
| Free Cash Flow | -$58.7M | -$86.1M | -$49.1M | -$15.9M | -$92.4M | -$95.7M | -$66.0M |
| FCF Margin | -85.4% | -176.6% | -195.5% | -13.8% | -380.6% | -430.3% | -6.2% |